Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Reactive oxygen species (ROS) release from neutrophils is a critical component of the innate immune response. Neutrophils generate and release ROS primarily through the activation of the NADPH oxidase complex (NOX2). This process, often referred to as the "respiratory burst," results in a rapid increase in oxygen consumption and production of superoxide anion, which serves as a precursor for other ROS. While essential for antimicrobial defense, dysregulated ROS release contributes to tissue injury in various diseases. Targeting this pathway therapeutically involves modulating ROS production to balance host defense and minimize tissue damage.
Modulation of ROS production by neutrophils, either inhibiting excessive release or stimulating deficient release.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reactive Oxygen Species Release from Neutrophils (None).